Nayzilam is a prescription rescue therapy that is used across domains where short-term symptom management is appropriate for acute, episodic neurological manifestations in patients with epilepsy aged 12 years and older.

Acute Management of Seizure Clusters and Symptomatic Relief

The medication is indicated for the acute treatment of distinct, frequent seizure events, specifically for seizure clusters and acute repetitive seizures (ARS). The drug is applied in conditions marked by episodic, heightened symptomatic distress that is noticeably different from a patient's usual seizure pattern. The medication is used for easing symptoms of increased neurological or muscular activity and may help address symptom clusters that may become intense or disruptive.

Supportive Relief and Out-of-Hospital Intervention

The support provided is relevant for easing symptomatic discomfort and assisting with stability when symptoms become more noticeable during an acute event. The use is aligned with clinical scenarios requiring short-term symptomatic assistance when symptoms intensify outside a professional medical setting, such as in the home, school, or work environment. This supports the patient during difficult episodes by easing distress and may assist with maintaining functional stability after symptomatic periods.

Quick Fact: Relief for Acute Repetitive Seizure Symptoms The medication is applied when groups of symptoms appear suddenly or fluctuate, helping to manage these challenging symptomatic periods.

Regulatory References

1. NIH MedlinePlus Drug Information

Official Eligibility and Contraindications for Nayzilam

Regulatory agencies define the eligibility for Nayzilam (midazolam nasal spray) based on specific patient demographics and pre-existing health conditions.

Eligibility Restrictions

Nayzilam must be used with extreme caution in populations with compromised respiratory function, such as those with severe COPD or sleep apnea. Caution is also required for patients with severe hepatic impairment due to potential impairment of drug metabolism.

Pregnancy and Lactation: Use late in pregnancy may result in neonatal withdrawal syndrome; midazolam is excreted in human milk, requiring caution during breastfeeding. Co-administration with opioids or other CNS depressants is subject to a Black Box Warning due to the heightened risk of profound sedation and respiratory depression.

Interactions with other medicines and products

Nayzilam (midazolam) exhibits officially documented interaction patterns primarily through two mechanisms: metabolism and additive central nervous system (CNS) effects. All interaction information is based on official government regulatory documents.

Pharmacokinetic Interactions (Metabolism)

Midazolam clearance is highly dependent on the Cytochrome P450 3A4 (CYP3A4) enzyme system. Co-administration with strong or moderate CYP3A4 inhibitors, such as certain antibiotics or antifungals, is officially restricted because they substantially reduce the clearance of the medicine.

Pharmacodynamic Interactions (CNS Effects)

Co-administration with other CNS depressants or opioids increases the risk of severe pharmacodynamic effects. The official labeling carries a serious warning that combining Nayzilam with opioids may result in a profound sedation, respiratory depression, coma, and death.

Non-Medicinal Substance Interactions

The use of Nayzilam in combination with alcohol may cause an increased CNS-depressant effect. Consumption of grapefruit juice is documented to increase midazolam exposure due to its enzyme inhibition properties.

Population-Specific Notes

The effects of these interactions may be more pronounced in certain populations. Slower clearance and prolonged exposure are noted in patients with hepatic impairment or renal impairment. Older, elderly patients face a greater risk of adverse reactions when the medicine is combined with other CNS depressants.

Nayzilam (midazolam) functions as a positive allosteric modulator of the central GABA-A receptor ( GABA A). This receptor is a ligand-gated ion channel composed of five subunits that, upon activation by the neurotransmitter GABA, permits the passage of chloride ions. Midazolam binds to a distinct allosteric site on the GABA A receptor, specifically located at the interface between the alpha1 and gamma2 subunits. Binding at this site does not directly activate the channel but instead induces a conformational change that increases the receptor's affinity for GABA. This modulation enhances the efficiency of the channel, leading to an increased frequency of chloride ion channel opening. The resulting influx of negatively charged chloride ions causes the neuron's interior to become more negative, a process known as hyperpolarization. Hyperpolarization stabilizes the neuronal membrane potential, thereby enhancing inhibitory neurotransmission and reducing the excitability required for the propagation of excessive neuronal firing within the central nervous system.

The usage protocol for Nayzilam is defined by precise instructions that govern the route, dose limits, and frequency of administration. This medication is supplied as a single-dose nasal spray unit and is administered exclusively via the intranasal route.

Official Administration Protocol

The standard protocol for treating an acute episode begins with a fixed initial quantity. The initial dose is one spray, which delivers 5 mg of midazolam into one nostril. A strict time interval must be observed before subsequent action. If further intervention is deemed necessary, a second dose (one spray, 5 mg) may be administered into the opposite nostril. This second dose can only be given 10 minutes after the first. The maximum treatment for a single acute episode is 2 doses (10 mg total).

Frequency and Contextual Use

Nayzilam is characterized as an intermittent rescue therapy and is explicitly not intended for daily use or chronic maintenance. To maintain this protocol, limits are defined for how often the treatment can be used. The medication must not be used to treat more than one episode every three days, with a monthly maximum of five episodes per month. The medication is indicated for use in patients who are 12 years of age and older.

Preparation and Applicability

Proper use requires attention to the device itself. The nasal spray unit is for single use only and must not be tested or primed prior to administration, as this would result in the loss of the dose.

Research evidence / Overview of Studies for Nayzilam

The research base for this product is primarily defined by clinical trials that were designed to study its use in acute seizure episodes. This overview focuses on the design of those studies, the patient groups evaluated, and what research indicates about short-term patterns and longer-term use, without making statements about results or individual treatment choices.

Evidence for the Acute Management of Seizure Clusters (Acute Repetitive Seizures)

The research evidence for this product was primarily gathered in a pivotal, Phase 3 Randomized Controlled Trial (RCT). This type of study is designed to compare the medication against an inactive substance (placebo) under controlled conditions. The research included adolescents and adults (aged 12 years and older) with documented epilepsy who experienced distinct episodes of frequent seizure activity.

The studies were applied in research contexts involving fluctuating or unstable symptoms, with a focus on acute events. Findings from the randomized trial described measurements of how often participants met the predefined endpoint, which assessed measures related to seizure cessation and the subsequent duration of time without a recurrence within a brief, specified time interval.

Study Focus: Seizure Cessation and Recurrence

Researchers examined two key outcomes: measures related to seizure cessation shortly after the nasal spray was given, and the length of time until the next seizure occurred, tracking observations for up to 24 hours. Research also explored measures reflecting daily functioning or activity level, specifically tracking the Time to Return to Full Baseline Function (RTFBF). This outcome is a measurement of the duration until participants returned to their usual, pre-seizure state.

Long-Term Data and Repeated Use Follow-Up

Research also included extensive Open-label Extension (OLE) studies, which evaluated repeated use of the product over longer periods in a home environment. These OLE studies did not include a placebo group but provided insight into long-term scenarios. The follow-up durations in these extension studies evaluated repeated use over median periods of approximately 17 months.

Understanding Evidence Gaps and Areas of Uncertainty

The research designed to study the acute event relies on a single pivotal Randomized Controlled Trial. The evidence regarding repeated, intermittent use over time was gathered through open-label studies, a design that lacks a placebo comparator and therefore comparative evidence is lacking relative to no treatment. Long-term effects are not fully established beyond the observation period of the open-label studies, and comparative evidence against other acute rescue therapies is also limited.

Common questions about Nayzilam (FAQ)

Q: How quickly is Nayzilam expected to start working after administration?

A: Official product information notes that if the acute seizure episode continues, the need for a second dose is assessed mathbf10 minutes after the initial dose. The mathbf10-minute period for re-assessment is used to guide whether further intervention is needed, indicating the immediate timeframe for expected effect. The medicine is designed for mathbfrapid systemic absorption to quickly intervene in seizure activity.

Q: What is the usual duration of effect for Nayzilam, according to studies?

A: Official safety information indicates that the medicine is associated with partial or complete mathbfimpairment of recall for the mathbfnext several hours after it is administered. This observation is consistent with the known characteristics of the medication.

Q: How is Nayzilam different from other benzodiazepine rescue medications for seizures?

A: Nayzilam is distinct because of its formulation and route of administration. It is the first benzodiazepine approved by the FDA that is specifically administered as a mathbfnasal spray for the acute treatment of seizure clusters. This unique nasal delivery system is noted in the official prescribing information.

Q: What should a patient generally know about driving or operating machinery after using Nayzilam?

A: Due to the potential for central nervous system depression, patients should mathbfavoid activities requiring mental alertness. This includes mathbfdriving or operating heavy machinery. Regulatory warnings advise that this mathbfavoidance should continue until the patient has returned to their usual baseline level of functioning.

Q: Is Nayzilam intended for all types of seizures?

A: Official regulatory documents indicate that Nayzilam is solely for the mathbfacute treatment of mathbfseizure clusters. These episodes are generally described as mathbfdistinct, frequent seizure events that repeat over a short time frame and differ from the patient’s typical seizures.

Q: Can Nayzilam be used by patients who are already taking a daily anti-seizure medication?

A: Nayzilam is indicated for acute intervention in patients who mathbfdo have epilepsy. The official prescribing information discusses potential mathbfinteractions with other medications, including daily anti-epileptic drugs, as part of the safety information.

Q: How does the FDA classify Nayzilam under the controlled substances act?

A: The FDA classifies Nayzilam as a mathbfSchedule IV (CIV) federally controlled substance. This classification is due to the presence of mathbfmidazolam, which is described in regulatory warnings as carrying a risk for abuse, misuse, and dependence.

Q: Does using Nayzilam cause confusion?

A: While common side effects include drowsiness and dizziness, mathbfconfusion or sudden severe mental changes are listed in official documents as potential signs of a more mathbfserious side effect or related to abuse or withdrawal. These symptoms are noted to be serious and should prompt immediate contact with a healthcare professional.

Q: Do patients need special training to use Nayzilam?

A: Official instructions require patients and caregivers to carefully read the detailed mathbfInstructions for Use before the medicine is administered. Regulatory information also notes that specific mathbftraining resources from the manufacturer are available to help patients and caregivers practice the proper use of the nasal spray device.

Q: What is the role of a caregiver when Nayzilam is administered?

A: According to the official prescribing information, Nayzilam is specifically designed to be administered by a mathbfnon-healthcare professional to the patient. This allows a mathbfcaregiver or loved one to provide immediate intervention during an acute seizure cluster episode outside of a hospital setting.

Official Storage and Disposal Requirements

Nayzilam (midazolam) nasal spray must be stored according to specific regulatory requirements to maintain its stability and effectiveness.

This information reflects the storage and disposal instructions mandated in the official prescribing information.